Convalescent Plasma in a Patient with Protracted COVID-19 and Secondary Hypogammaglobulinemia Due to Chronic Lymphocytic Leukemia: Buying Time to Develop Immunity?

Jaap L. J. Hanssen; Johan Stienstra; Stefan A. Boers; Cilia R. Pothast; Hans L. Zaaijer; Jennifer M. Tjon; Mirjam H. M. Heemskerk; Mariet C. W. Feltkamp; Sandra M. Arend

doi:10.3390/idr13040077

Convalescent Plasma in a Patient with Protracted COVID-19 and Secondary Hypogammaglobulinemia Due to Chronic Lymphocytic Leukemia: Buying Time to Develop Immunity?

Jaap L. J. Hanssen^*
, Johan Stienstra
, Stefan A. Boers
, Cilia R. Pothast
, Hans L. Zaaijer
, Jennifer M. Tjon
, Mirjam H. M. Heemskerk
, Mariet C. W. Feltkamp
, Sandra M. Arend

^*Corresponding author for this work

Affiliatie UvA

Leiden University Medical Center
Sanquin Blood Supply Foundation

Research output: Contribution to journal › Article › Academic › peer-review

15 Downloads (Pure)

Abstract

It is not exactly clear yet which type of immune response prevails to accomplish viral clearance in coronavirus disease 2019 (COVID-19). Studying a patient with chronic lymphocytic leukemia and hypogammaglobulinemia who suffered from COVID-19 provided insight in the immunological responses after treatment with COVID-19 convalescent plasma (CCP). Treatment consisted of oxygen, repeated glucocorticosteroids and multiple dosages of CCP guided by antibody levels. Retrospectively performed humoral and cellular immunity analysis made clear that not every serological test for COVID-19 is appropriate for follow-up of sufficient neutralizing antibodies after CCP. In retrospect, we think that CCP merely bought time for this patient to develop an adequate cellular immune response which led to viral clearance and ultimately clinical recovery.

Original language	English
Pages (from-to)	855-864
Number of pages	10
Journal	Infectious disease reports
Volume	13
Issue number	4
DOIs	https://doi.org/10.3390/idr13040077
Publication status	Published - 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

COVID-19
Chronic lymphocytic leukemia
Convalescent plasma
In vitro T cell assay

Access to Document

10.3390/idr13040077

Convalescent-plasma-in-a-patient-with-protracted-covid-19-and-secondary-hypogammaglobulinemia-due-to-chronic-lymphocytic.pdfFinal published version, 850 KBLicence: CC BY

Cite this

Hanssen, J. L. J., Stienstra, J., Boers, S. A., Pothast, C. R., Zaaijer, H. L., Tjon, J. M., Heemskerk, M. H. M., Feltkamp, M. C. W., & Arend, S. M. (2021). Convalescent Plasma in a Patient with Protracted COVID-19 and Secondary Hypogammaglobulinemia Due to Chronic Lymphocytic Leukemia: Buying Time to Develop Immunity? Infectious disease reports, 13(4), 855-864. https://doi.org/10.3390/idr13040077

@article{2bf43a2a041245ec838df90d2d82b407,

title = "Convalescent Plasma in a Patient with Protracted COVID-19 and Secondary Hypogammaglobulinemia Due to Chronic Lymphocytic Leukemia: Buying Time to Develop Immunity?",

abstract = "It is not exactly clear yet which type of immune response prevails to accomplish viral clearance in coronavirus disease 2019 (COVID-19). Studying a patient with chronic lymphocytic leukemia and hypogammaglobulinemia who suffered from COVID-19 provided insight in the immunological responses after treatment with COVID-19 convalescent plasma (CCP). Treatment consisted of oxygen, repeated glucocorticosteroids and multiple dosages of CCP guided by antibody levels. Retrospectively performed humoral and cellular immunity analysis made clear that not every serological test for COVID-19 is appropriate for follow-up of sufficient neutralizing antibodies after CCP. In retrospect, we think that CCP merely bought time for this patient to develop an adequate cellular immune response which led to viral clearance and ultimately clinical recovery.",

keywords = "COVID-19, Chronic lymphocytic leukemia, Convalescent plasma, In vitro T cell assay",

author = "Hanssen, \{Jaap L. J.\} and Johan Stienstra and Boers, \{Stefan A.\} and Pothast, \{Cilia R.\} and Zaaijer, \{Hans L.\} and Tjon, \{Jennifer M.\} and Heemskerk, \{Mirjam H. M.\} and Feltkamp, \{Mariet C. W.\} and Arend, \{Sandra M.\}",

note = "Funding Information: The authors thank the patient described in this report for his cooperation and all medical personnel caring for or providing diagnostic facilities to COVID-19 patients for their continuous efforts in these unusual times. Publisher Copyright: {\textcopyright} 2021 Page Press Publications. All rights reserved.",

year = "2021",

doi = "10.3390/idr13040077",

language = "English",

volume = "13",

pages = "855--864",

journal = "Infectious disease reports",

issn = "2036-7430",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "4",

}

Hanssen, JLJ, Stienstra, J, Boers, SA, Pothast, CR, Zaaijer, HL, Tjon, JM, Heemskerk, MHM, Feltkamp, MCW & Arend, SM 2021, 'Convalescent Plasma in a Patient with Protracted COVID-19 and Secondary Hypogammaglobulinemia Due to Chronic Lymphocytic Leukemia: Buying Time to Develop Immunity?', Infectious disease reports, vol. 13, no. 4, pp. 855-864. https://doi.org/10.3390/idr13040077

Convalescent Plasma in a Patient with Protracted COVID-19 and Secondary Hypogammaglobulinemia Due to Chronic Lymphocytic Leukemia: Buying Time to Develop Immunity? / Hanssen, Jaap L. J.; Stienstra, Johan; Boers, Stefan A. et al.
In: Infectious disease reports, Vol. 13, No. 4, 2021, p. 855-864.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Convalescent Plasma in a Patient with Protracted COVID-19 and Secondary Hypogammaglobulinemia Due to Chronic Lymphocytic Leukemia

T2 - Buying Time to Develop Immunity?

AU - Hanssen, Jaap L. J.

AU - Stienstra, Johan

AU - Boers, Stefan A.

AU - Pothast, Cilia R.

AU - Zaaijer, Hans L.

AU - Tjon, Jennifer M.

AU - Heemskerk, Mirjam H. M.

AU - Feltkamp, Mariet C. W.

AU - Arend, Sandra M.

N1 - Funding Information: The authors thank the patient described in this report for his cooperation and all medical personnel caring for or providing diagnostic facilities to COVID-19 patients for their continuous efforts in these unusual times. Publisher Copyright: © 2021 Page Press Publications. All rights reserved.

PY - 2021

Y1 - 2021

N2 - It is not exactly clear yet which type of immune response prevails to accomplish viral clearance in coronavirus disease 2019 (COVID-19). Studying a patient with chronic lymphocytic leukemia and hypogammaglobulinemia who suffered from COVID-19 provided insight in the immunological responses after treatment with COVID-19 convalescent plasma (CCP). Treatment consisted of oxygen, repeated glucocorticosteroids and multiple dosages of CCP guided by antibody levels. Retrospectively performed humoral and cellular immunity analysis made clear that not every serological test for COVID-19 is appropriate for follow-up of sufficient neutralizing antibodies after CCP. In retrospect, we think that CCP merely bought time for this patient to develop an adequate cellular immune response which led to viral clearance and ultimately clinical recovery.

AB - It is not exactly clear yet which type of immune response prevails to accomplish viral clearance in coronavirus disease 2019 (COVID-19). Studying a patient with chronic lymphocytic leukemia and hypogammaglobulinemia who suffered from COVID-19 provided insight in the immunological responses after treatment with COVID-19 convalescent plasma (CCP). Treatment consisted of oxygen, repeated glucocorticosteroids and multiple dosages of CCP guided by antibody levels. Retrospectively performed humoral and cellular immunity analysis made clear that not every serological test for COVID-19 is appropriate for follow-up of sufficient neutralizing antibodies after CCP. In retrospect, we think that CCP merely bought time for this patient to develop an adequate cellular immune response which led to viral clearance and ultimately clinical recovery.

KW - COVID-19

KW - Chronic lymphocytic leukemia

KW - Convalescent plasma

KW - In vitro T cell assay

UR - https://www.scopus.com/pages/publications/85117102558

U2 - 10.3390/idr13040077

DO - 10.3390/idr13040077

M3 - Article

C2 - 34698153

SN - 2036-7430

VL - 13

SP - 855

EP - 864

JO - Infectious disease reports

JF - Infectious disease reports

IS - 4

ER -

Convalescent Plasma in a Patient with Protracted COVID-19 and Secondary Hypogammaglobulinemia Due to Chronic Lymphocytic Leukemia: Buying Time to Develop Immunity?

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this